poisar

Stocks · News reference

Genelux Says Frontiers In Oncology Published Case Report Of Platinum-Relapsed Small Cell Lung Cancer Patient Achieving 16.7 Months Progression-Free Survival And 84.6% Target Lesion Reduction After Olvi-Vec And Platinum Rechallenge

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GNLX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate

    Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 5 percent decrease over losses of $(0.20) per share from the same

    GNLX